2025-12-19 - Analysis Report
Okay, here's a comprehensive report on Lam Research (LRCX) based on the provided data.

**1) Return Rate Comparison & Analysis**

*   **Ticker:** LRCX
*   **Company Overview:** Lam Research Corp designs, manufactures, markets, and services semiconductor processing equipment used in the fabrication of integrated circuits.
*   **LRCX Cumulative Return:** 242.86%
*   **S&P 500 (VOO) Cumulative Return:** 99.09%
*   **Divergence:**
    *   Maximum: 148.4
    *   Minimum: -15.5
    *   Current: 140.1
    *   Relative Divergence: 94.9

**Analysis:** LRCX has significantly outperformed the S&P 500 over the measured period. The current divergence is high, sitting near the top of its historical range. The *relative divergence* of 94.9 indicates that the outperformance is currently near its highest level relative to the past fluctuations.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 84.0%   | 67.8%   | 56.0%   | 0.0   | 23.2   |
| 2016-2018  | 18.0%   | 68.1%   | 3.0%    | 0.1   | 17.2   |
| 2017-2019  | 53.0%   | 82.9%   | 31.0%   | 1.2   | 36.9   |
| 2018-2020  | 66.0%   | 82.9%   | 42.0%   | 1.1   | 59.5   |
| 2019-2021  | 119.0%  | 82.9%   | 73.0%   | 1.0   | 90.7   |
| 2020-2022  | -10.0%  | 79.2%   | -9.0%   | 0.9   | 53.0   |
| 2021-2023  | -13.0%  | 80.4%   | -15.0%  | 1.0   | 98.8   |
| 2022-2024  | -52.0%  | 80.4%   | -72.0%  | 1.0   | 91.1   |
| 2023-2025  | 154.0%  | 80.4%   | 90.0%   | 0.9   | 207.7  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly, showing high growth periods (e.g., 2015-2017, 2019-2021, 2023-2025) and some periods of decline (2020-2022, 2021-2023, 2022-2024).
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and potential for large losses from peak to trough.
*   **Alpha:** Alpha, which measures performance relative to a benchmark, is generally positive in high-growth periods and negative during declines, as expected. A high alpha suggests the stock is generating returns beyond what is explained by the market.
*   **Beta:** Beta hovers around 1, suggesting the stock's volatility is similar to the overall market.
*   **Cap(B):** Market capitalization shows general increase over time, reflecting the company's growth (despite periods of negative CAGR).

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 164.70
*   **Last-market:** {'price': 164.7, 'previousClose': 154.98, 'change': 6.27}
*   **5-day SMA:** 161.55
*   **20-day SMA:** 157.996
*   **60-day SMA:** 151.4038

**Analysis:** The stock price is above all three Simple Moving Averages (SMAs), suggesting an upward trend. The price has seen a strong recent increase (change of 6.27), and the 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, further reinforcing the short-term upward momentum.

**3) RSI, PPO, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 58.30 (Neutral)
*   **PPO:** -0.1431 (Slightly oversold)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-04)
*   **Recent (20 days) relative divergence change:** -3.7 (Negative: Short-term Decline)
*   **Expected Return (%):** 16.1%

**Analysis:**

*   The **MRI** suggests a medium level of risk and a recommendation for investment.
*   The **RSI** is at 58.3, indicating neutral momentum; neither overbought nor oversold.
*   The **PPO** is slightly negative, suggesting a minor oversold condition.
*   The **Hybrid Signal** recommends a strong buy signal, allocating a large portion of capital.
*   The recent decrease in relative divergence suggests that the stock's outperformance relative to the S\&P 500 has slightly decreased in the past 20 days.
*   The **Expected Return** of 16.1% is attractive and suggests potential for outperformance compared to the S&P 500 over the long term.

**4) Recent News & Significant Events**

The news headlines suggest a mixed outlook:

*   **Positive:** Articles highlighting the stock's upward movement ("Lam Research Stock Soars: Time to Buy?", "Why Lam Research (LRCX) Stock Is Up Today") and analysts raising price targets ("Jefferies Lifts Target to $200", "Analyst Raises Price Target to $195").
*   **Negative:** An article reporting insider selling ("Insider Sale: President and CEO of $LRCX Sells 113,300 Shares"). Insider selling can sometimes be perceived negatively by investors, though it doesn't always indicate a lack of confidence in the company.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.79)
*   **Opinions:** 30
*   **Target Price:**
    *   Average: $164.47
    *   High: $210.00
    *   Low: $84.00

**Analysis:**

*   The analyst consensus is strongly bullish, with a "Buy" rating.
*   The average target price is around the current price level, indicating only marginal expected gains on average from analyst perspective.
*   The high target price suggests some analysts are very optimistic about the stock's potential.
*   The low target price reveals there are analysts are very pessimistic about the stock's potential.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-10-24 | 1.24 | 5.32 B$     |
| 2025-04-25 | 1.04 | 4.72 B$     |
| 2025-01-31 | 0.93 | 4.38 B$     |
| 2024-10-28 | 0.86 | 4.17 B$     |
| 2025-10-24 | 0.86 | 4.17 B$     |

**Analysis:** Both EPS (Earnings Per Share) and Revenue have generally been increasing over the past few quarters, indicating solid financial performance. There is a jump in the most recent quarter (2025-10-24).

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | \$5.32B   | 50.43%        |
| 2025-06-30   | \$5.17B   | 50.08%        |
| 2025-03-31   | \$4.72B   | 49.02%        |
| 2024-12-31   | \$4.38B   | 47.37%        |
| 2024-09-30   | \$4.17B   | 48.05%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE    |
|--------------|----------|--------|
| 2025-09-30   | \$10.19B | 15.39% |
| 2025-06-30   | \$9.86B  | 17.44% |
| 2025-03-31   | \$9.51B  | 13.99% |
| 2024-12-31   | \$8.81B  | 13.52% |
| 2024-09-30   | \$8.47B  | 13.18% |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing, indicating strong sales growth.
*   **Profit Margin:** The profit margin is very high and above 50%, suggesting good cost control and pricing power.
*   **Equity:** Equity is also steadily increasing, reflecting the company's accumulation of assets.
*   **ROE:** Return on Equity is high and in the double digits, indicating efficient use of shareholder equity to generate profits.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** Lam Research has significantly outperformed the S&P 500, but its relative divergence is near its peak, implying potential for mean reversion. High recent CAGR, but negative CAGR in some historical periods.
*   **Technicals:** The stock is in an uptrend, supported by moving averages. RSI is neutral.
*   **Sentiment:** Analyst sentiment is strongly positive, but there's an insider sale to consider.
*   **Financials:** Excellent recent earnings and solid financial metrics (revenue growth, high profit margins, increasing equity, and strong ROE).
*   **Risk:** The MDD and Beta show there is high volatility, which means there can be a large downside.

**Conclusion:** Lam Research appears to be a strong company with good growth prospects, but potential investors should be aware of the recent high relative divergence and the possibility of volatility. The recent news of insider selling warrants further investigation.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.